Metraipolis › archive › dc_78c67752e441

Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study — Europe PMC PMID:40976915

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40976915
DOI
10.2340/1651-226x.2025.44327
License (as archived)
solo-consultazione
Archived
2026-11-09T20:25:10.136Z
SHA-256 of the archived text
09f865639ee813d48e4717b630bf07ff7a413e1f54bd442e168e53f4c19e8502
Stable URL of this page
https://metraipolis.com/documento/dc_78c67752e441

How to cite

Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study — Europe PMC PMID:40976915 — Europe PMC (en), https://europepmc.org/article/MED/40976915 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_78c67752e441 (Metraipolis archive dc_78c67752e441, sha256 09f865639ee813d48e4717b630bf07ff7a413e1f54bd442e168e53f4c19e8502)
BibTeX
@misc{dc78c67752e441,
  title = {Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study — Europe PMC PMID:40976915},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40976915},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_78c67752e441; sha256 09f865639ee813d48e4717b630bf07ff7a413e1f54bd442e168e53f4c19e8502},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40976915. Agents can read the archived copy with the MCP tool read_document.